Free Trial

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Anika Therapeutics, Inc. stock logo
ANIK
Anika Therapeutics
$24.76
+0.8%
$25.80
$16.54
$28.67
$367.19M0.7475,279 shs35,007 shs
NeuroPace, Inc. stock logo
NPCE
NeuroPace
$7.09
-5.8%
$12.08
$3.80
$18.15
$203.98M2.06107,966 shs105,720 shs
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
$13.32
+17.2%
$8.10
$3.78
$13.62
$735.60M1.73189,664 shs389,350 shs
Surmodics, Inc. stock logo
SRDX
Surmodics
$35.10
+2.1%
$29.76
$17.73
$39.41
$500.53M1.0461,649 shs42,927 shs
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Anika Therapeutics, Inc. stock logo
ANIK
Anika Therapeutics
+0.77%-3.84%-3.17%-0.04%-9.54%
NeuroPace, Inc. stock logo
NPCE
NeuroPace
-5.84%-10.82%-47.05%-57.65%+57.56%
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
+17.15%+36.90%+85.26%+31.10%+117.65%
Surmodics, Inc. stock logo
SRDX
Surmodics
+2.09%+0.60%+34.12%+7.80%+98.64%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Anika Therapeutics, Inc. stock logo
ANIK
Anika Therapeutics
3.3234 of 5 stars
2.31.00.03.62.71.71.9
NeuroPace, Inc. stock logo
NPCE
NeuroPace
3.0421 of 5 stars
3.43.00.00.02.74.20.6
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
1.247 of 5 stars
0.00.00.04.23.45.00.0
Surmodics, Inc. stock logo
SRDX
Surmodics
4.1008 of 5 stars
3.52.00.03.42.11.71.9

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Anika Therapeutics, Inc. stock logo
ANIK
Anika Therapeutics
2.50
Moderate Buy$29.5019.14% Upside
NeuroPace, Inc. stock logo
NPCE
NeuroPace
2.86
Moderate Buy$15.67120.97% Upside
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
N/AN/AN/AN/A
Surmodics, Inc. stock logo
SRDX
Surmodics
3.00
Buy$57.0062.39% Upside

Current Analyst Ratings

Latest NPCE, PLSE, ANIK, and SRDX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/9/2024
Anika Therapeutics, Inc. stock logo
ANIK
Anika Therapeutics
Barrington Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$37.00 ➝ $37.00
5/9/2024
NeuroPace, Inc. stock logo
NPCE
NeuroPace
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$18.00
5/2/2024
Surmodics, Inc. stock logo
SRDX
Surmodics
Barrington Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$71.00 ➝ $71.00
5/1/2024
Surmodics, Inc. stock logo
SRDX
Surmodics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$47.00 ➝ $43.00
4/10/2024
Surmodics, Inc. stock logo
SRDX
Surmodics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$47.00
3/14/2024
Anika Therapeutics, Inc. stock logo
ANIK
Anika Therapeutics
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingEqual Weight ➝ Equal Weight$22.00
3/14/2024
Anika Therapeutics, Inc. stock logo
ANIK
Anika Therapeutics
Barrington Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$29.00 ➝ $37.00
3/14/2024
NeuroPace, Inc. stock logo
NPCE
NeuroPace
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeEqual Weight ➝ Overweight$16.00 ➝ $20.00
3/6/2024
NeuroPace, Inc. stock logo
NPCE
NeuroPace
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$9.00 ➝ $13.00
3/6/2024
NeuroPace, Inc. stock logo
NPCE
NeuroPace
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$16.00 ➝ $18.00
(Data available from 5/29/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Anika Therapeutics, Inc. stock logo
ANIK
Anika Therapeutics
$166.66M2.20$4.96 per share4.99$14.50 per share1.71
NeuroPace, Inc. stock logo
NPCE
NeuroPace
$65.42M3.12N/AN/A$0.79 per share8.97
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
$700K1,050.85N/AN/A$0.81 per share16.44
Surmodics, Inc. stock logo
SRDX
Surmodics
$132.58M3.78$0.80 per share43.84$8.48 per share4.14

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Anika Therapeutics, Inc. stock logo
ANIK
Anika Therapeutics
-$82.67M-$5.25N/A18.762.28-45.39%0.48%0.39%8/13/2024 (Estimated)
NeuroPace, Inc. stock logo
NPCE
NeuroPace
-$32.96M-$1.19N/AN/AN/A-45.61%-173.62%-30.89%8/13/2024 (Estimated)
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
-$42.21M-$0.81N/AN/AN/A-86.15%-66.87%8/8/2024 (Estimated)
Surmodics, Inc. stock logo
SRDX
Surmodics
-$1.54M$0.9536.951,755.00N/A9.44%13.30%8.63%8/7/2024 (Estimated)

Latest NPCE, PLSE, ANIK, and SRDX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2024Q1 2024
Anika Therapeutics, Inc. stock logo
ANIK
Anika Therapeutics
$0.13$0.09-$0.04$0.49$39.23 million$40.52 million
5/8/2024Q1 2024
NeuroPace, Inc. stock logo
NPCE
NeuroPace
-$0.32-$0.32N/A-$0.32$18.12 million$18.12 million
5/7/2024Q1 2024
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
N/A-$0.17-$0.17-$0.16N/AN/A
5/1/2024Q2 2024
Surmodics, Inc. stock logo
SRDX
Surmodics
-$0.36$0.07+$0.43$0.12$28.79 million$31.96 million    
3/28/2024Q4 2023
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
N/A-$0.21-$0.21-$0.20N/AN/A
3/13/2024Q4 2023
Anika Therapeutics, Inc. stock logo
ANIK
Anika Therapeutics
-$0.15$0.05+$0.20$4.40$41.51 million$42.97 million
3/5/2024Q4 2023
NeuroPace, Inc. stock logo
NPCE
NeuroPace
-$0.33-$0.23+$0.10-$0.23$17.74 million$18.01 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Anika Therapeutics, Inc. stock logo
ANIK
Anika Therapeutics
N/AN/AN/AN/AN/A
NeuroPace, Inc. stock logo
NPCE
NeuroPace
N/AN/AN/AN/AN/A
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
N/AN/AN/AN/AN/A
Surmodics, Inc. stock logo
SRDX
Surmodics
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Anika Therapeutics, Inc. stock logo
ANIK
Anika Therapeutics
N/A
5.59
3.85
NeuroPace, Inc. stock logo
NPCE
NeuroPace
4.05
6.43
5.56
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
N/A
7.06
7.06
Surmodics, Inc. stock logo
SRDX
Surmodics
0.24
4.39
3.59

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Anika Therapeutics, Inc. stock logo
ANIK
Anika Therapeutics
91.53%
NeuroPace, Inc. stock logo
NPCE
NeuroPace
78.83%
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
76.95%
Surmodics, Inc. stock logo
SRDX
Surmodics
96.63%

Insider Ownership

CompanyInsider Ownership
Anika Therapeutics, Inc. stock logo
ANIK
Anika Therapeutics
5.85%
NeuroPace, Inc. stock logo
NPCE
NeuroPace
22.20%
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
71.50%
Surmodics, Inc. stock logo
SRDX
Surmodics
8.90%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Anika Therapeutics, Inc. stock logo
ANIK
Anika Therapeutics
35714.83 million13.96 millionOptionable
NeuroPace, Inc. stock logo
NPCE
NeuroPace
17128.77 million22.38 millionOptionable
Pulse Biosciences, Inc. stock logo
PLSE
Pulse Biosciences
5655.23 million15.74 millionOptionable
Surmodics, Inc. stock logo
SRDX
Surmodics
37614.26 million12.99 millionOptionable

NPCE, PLSE, ANIK, and SRDX Headlines

Recent News About These Companies

Surmodics (NASDAQ:SRDX) PT Lowered to $43.00

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Anika Therapeutics logo

Anika Therapeutics

NASDAQ:ANIK
Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief. The company's joint preservation and restoration product family comprises and orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions. In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and Hyalomatrix used for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.
NeuroPace logo

NeuroPace

NASDAQ:NPCE
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
Pulse Biosciences logo

Pulse Biosciences

NASDAQ:PLSE
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.
Surmodics logo

Surmodics

NASDAQ:SRDX
Surmodics, Inc., together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for neurovascular, peripheral, coronary, and structural heart, and other markets, as well as manufacturing of vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. The IVD segment develops, manufactures, and sells chemical and biological components for in vitro diagnostic immunoassay and molecular tests, as well as diagnostic and biomedical research markets. This segment offers protein stabilizers, substrates, surface coatings, and antigens. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota.